Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain
| العنوان: | Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain |
|---|---|
| المؤلفون: | Mar Guilarte, Anna Sala-Cunill, María Luisa Baeza, Rosario Cabañas, María Dolores Hernández, Ethel Ibañez, Carlos Hernando de Larramendi, Ramon Lleonart, Teófilo Lobera, Luis Marqués, Blanca Sáenz de San Pedro, Jaco Botha, Irmgard Andresen, Teresa Caballero, for the IOS Study Group |
| المساهمون: | Institut Català de la Salut, [Guilarte M, Sala-Cunill A] Secció d’Al•lèrgia, Servei de Medicina, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Research Network on Allergy (National Allergy Network ARADyAL: Asma, Reacciones Adversas y Alérgicas), Instituto de Salud Carlos III, Madrid, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Baeza ML] Allergy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Biomedical Research Network on Rare Diseases, CIBERER-U761, Gregorio Marañón Health Research Institute, Madrid, Spain. [Cabañas R] Allergy Department, Hospital Universitario La Paz, Hospital La Paz Institute for Health Research (IdiPaz), Madrid, Spain. Biomedical Research Network on Rare Diseases, CIBERER-U754, Madrid, Spain. [Hernández MD, Ibañez E] Allergy Department, IIS-Hospital Universitari I Politècnic La Fe, Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology Allergy, Asthma & Clinical Immunology, Vol 17, Iss 1, Pp 1-11 (2021) Scientia |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Hereditary angioedema, Therapeutics::Patient Care::Time-to-Treatment [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Research, Malalties congènites - Tractament, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], enfermedades del sistema inmune::hipersensibilidad::hipersensibilidad inmediata::urticaria::angioedema::angioedemas hereditarios [ENFERMEDADES], General Medicine, RC581-607, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Bradykinin, Inflamació, Immune System Diseases::Hypersensitivity::Hypersensitivity, Immediate::Urticaria::Angioedema::Angioedemas, Hereditary [DISEASES], Spain, terapéutica::asistencia al paciente::tiempo hasta el tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Proteïna C - Deficiència, Icatibant, Bradykinin B2 receptor antagonists, On-demand treatment, Registries, Immunologic diseases. Allergy |
| الوصف: | Bradykinin; Hereditary angioedema; Icatibant Bradicinina; Angioedema hereditario; Icatibant Bradicinina; Angioedema hereditari; Icatibant Background The Icatibant Outcome Survey (IOS) is an international registry monitoring the use of icatibant, a bradykinin B2 receptor antagonist indicated for the acute treatment of hereditary angioedema (HAE) attacks. Our goal was to assess disease characteristics and icatibant treatment outcomes in patients with HAE due to C1 inhibitor deficiency (HAE type 1 or 2 (HAE-1/2)) from Spain relative to other countries participating in IOS. Methods Descriptive retrospective analyses of data are reported from 10 centers in Spain vs 51 centers in 12 other participating countries (July 2009 to January 2019). Results No meaningful differences were identified between patients in Spain (n = 119) and patients across other countries (n = 907) regarding median age at symptom onset (15.0 vs 12.0 years) or diagnosis (22.3 vs 20.5 years). Overall HAE attack rates (total attacks/total years of follow-up) were 2.66 in Spain and 1.46 across other countries. Patients in Spain reported fewer severe/very severe HAE attacks before treatment (41.0% vs 45.9%; P |
| وصف الملف: | application/pdf |
| تدمد: | 1710-1484 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5a93368e3638b37df9d2c8e90768d15Test https://pubmed.ncbi.nlm.nih.gov/34965883Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f5a93368e3638b37df9d2c8e90768d15 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17101484 |
|---|